此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Patient Study to Evaluate the Safety and Emollient Performance of Doublebase Once in the Treatment of Psoriasis

2026年9月11日 更新者:Dermal Laboratories Ltd
This PMCF study is to obtain patient feedback using online questionnaires. There will be no involvement from healthcare professionals (HCPs) or investigator sites. Up to 100 Patients are being recruited by My Health Focus through their website. The study is performed throughout the UK except Northern Ireland with no sites involved in this study. Patients apply directly to participate in the study and the testing and questionnaire responses are completed at home.

研究概览

地位

尚未招聘

条件

详细说明

The study is to be performed in liaison with My Health Focus who have been set up to help support, educate and promote research for psoriasis patients. The intention is to utilise their website and patient database to recruit to this study under the management of My Health Focus. This will allow psoriasis patients to access this treatment free of charge and for the Sponsor to obtain key information about how psoriasis patients use Doublebase Once.

Psoriasis patients registered on the My Health Focus database will be advised about the study by adverts on the My Health Focus website or social medial posts and direct email via My Health Focus mailing list. This will briefly summarise the study, the rationale for performing it, and a description of what participation will involve. Any patients interested in taking part will then be asked to register interest by completing a short questionnaire that will be used as a pre-screen tool to exclude any patients who are ineligible for the study.

Patients will then be provided with the Patient Information Sheet (PIS) to read and then complete a consent questionnaire, confirming their agreement to participate in the study. Once consent and assent (where applicable) have been obtained, patients will then complete a screening questionnaire and provide details to fulfil their supplies. My Health Focus and the Sponsor will require access to personal information such as email addresses (for sending the questionnaires and safety monitoring) and home addresses (for sending the packs of Doublebase Once), but these details will be used solely for the purpose of the study.

If all screening questions are completed and the patient is eligible in accordance with the inclusion and exclusion criteria, the patient will then be sent two pump pack of Doublebase Once 500g.

On receipt of their pack(s) of Doublebase Once (Day 0), the patients will be asked to read through all the information provided and to complete an online questionnaire and, if they agreed at consent, they will be asked to photograph one area of their psoriasis that will be treated with the product and upload to the database alongside their questionnaire. Guidance on taking the photos will be provided in the questionnaire with regards to lighting, location, distance, angle of taking photographs, and background. This questionnaire and image(s) will form the baseline 'before using Doublebase Once' and there will be some questions to be completed immediately after first use of the product.

Patients will then be asked to use Doublebase Once, as per the package leaflet for approximately 4 weeks, once daily (unless they need to use it more often) and on their affected psoriasis areas, instead of their usual leave-on emollient. Patients will also be asked to use Doublebase Once instead of their usual wash product. If patients do not want to use Doublebase Once instead of their usual wash products, they will be asked to continue to use their usual products.

While using the product, the patients will be sent further questionnaires to complete on Day 8 and 29 and if they consented to do so, to send further photographs of the same area taken at Day 0.

At the end of the study as part of the final questionnaire, patients will be asked to provide a short review about Doublebase Once and give the product a 'star rating' out of 5 (5 being excellent and 1 being poor).

研究类型

介入性

注册 (估计的)

100

阶段

  • 不适用

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子
  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • Patients with psoriasis of any severity previously diagnosed by a Healthcare Professional (HCP).
  • Patients normally managing their skin condition by regular and ongoing use of leave-on emollient(s).
  • Patients willing to incorporate Doublebase Once into their normal skin condition management routine for approximately 1 month as their only emollient and instead of their usual emollient

Exclusion Criteria:

  • Does not regularly use an emollient
  • Known history of intolerance or skin sensitivity to any of the ingredients of Doublebase Once (as identified on the Patient Information Sheet and product labelling), or similar products used.
  • Currently participating in a study involving an investigational medicinal product/medical device or having participated in the previous 30 days.
  • Patients currently residing in Northern Ireland (this is due to the different approval process)
  • Patients (or their parents/legal guardians, in the case of infants, very young children or adolescent adults) who may have difficulties completing the feedback questionnaires, which will be written in English only.
  • Employees of My Health Focus or the Sponsor (Dermal or the Diomed group companies), or any immediate family member (partner, offspring, parents, siblings or sibling's offspring) of such employees

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Main Group
Doublebase Once
Once Daily Emollient

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Emollient performance
大体时间:4 weeks use
Patient reported questionnaire responses on skin condition and product use. Scoring of 0 - 10 to specific skin condition and product parameters (0=Strongly agree - 10 strongly disagree)
4 weeks use

其他结果措施

结果测量
措施说明
大体时间
Adverse Device effects and Device deficiencies
大体时间:weeks 1 - 4
Reported related adverse device effects and Device deficiencies
weeks 1 - 4

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年9月21日

初级完成 (估计的)

2026年10月31日

研究完成 (估计的)

2026年10月31日

研究注册日期

首次提交

2026年8月20日

首先提交符合 QC 标准的

2026年9月11日

首次发布 (实际的)

2026年9月14日

研究记录更新

最后更新发布 (实际的)

2026年9月14日

上次提交的符合 QC 标准的更新

2026年9月11日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

关键字

其他研究编号

  • DLPF-04

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Patient Reported Outcomes

IPD 共享时间框架

Dec 2026

IPD 共享支持信息类型

  • 研究方案
  • 树液

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅